Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability study of MY008211A tablets in patients with paroxysmal nocturnal hemoglobinuria
CTR20241816Phase 3Active
- Sponsor
- Meiyue Biotech
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MY-008 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Meiyue Biotech. Started Jun 2024; status: active.
02
Drugs
MY-008
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20241816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241816.